公开(公告)号：US11524080B2

公开(公告)日：2022-12-13

申请号：US17273059

申请日：2019-09-13

申请人： THE SECRETARY OF STATE FOR DEFENCE ,  THE UNIVERSITY OF STRATHCLYDE

发明人： Ethel Diane Williamson ,  Riccardo Vincenzo D'Elia ,  Craig William Roberts ,  Stuart Woods

IPC分类号： A61K47/69 ,  A61K47/54 ,  A61P31/14 ,  A61P31/04 ,  A61K9/127 ,  A61K31/496 ,  A61K31/513 ,  A61K31/5383 ,  A61K31/65 ,  A61K31/711 ,  A61K38/21 ,  A61K47/14 ,  A61K47/24 ,  A61K47/26 ,  A61K47/28 ,  A61K47/42 ,  C07K16/10

摘要： The invention relates to methods for the preparation of a pharmaceutical-vesicle formulation comprising steps of: preparing and processing vesicle components and a pharmaceutical agent to entrap the pharmaceutical agent in the vesicle and form a pharmaceutical-vesicle formulation, wherein the pharmaceutical-vesicle formulation is reconstituted in a known quantity of the pharmaceutical agent dissolved in a pharmaceutically-acceptable carrier to provide a biphasic pharmaceutical-vesicle formulation. The invention also relates to the associated pharmaceutical-vesicle formulations, pharmaceutical kits and uses as a medicament, in particular for the prevention or treatment of infection by bacteria such as Burkholderia pseudomallei and Francisella tularensis, and viruses such as Venezuelan Equine Encephalitis Virus (VEEV).

公开(公告)号：US09346860B2

公开(公告)日：2016-05-24

申请号：US13627071

申请日：2012-09-26

申请人： THE SECRETARY OF STATE FOR DEFENCE

发明人： Ethel Diane Williamson ,  Julie Miller ,  Nicola Jane Walker ,  Leslie William James Baillie ,  Paula Thomson Holden ,  Helen Claire Flick-Smith ,  Helen Lisa Bullifent ,  Richard William Titball ,  Andrew William Topping

IPC分类号： C12N15/70 ,  C07K14/32 ,  A61K39/00

CPC分类号： C07K14/32 ,  A61K39/00 ,  C07K2319/00 ,  C12N15/70

摘要： An immunogenic reagent which produces an immune response which is protective against Bacillus anthracis, said reagent comprising one or more polypeptides which together represent up to three domains of the full length Protective Antigen (PA) of B. anthracis or variants of these, and at least one of said domains comprises domain 1 or domain 4 of PA or a variant thereof. The polypeptides of the immunogenic reagent as well as full length PA are produced by expression from E. coli. High yields of polypeptide are obtained using this method. Cells, vectors and nucleic acids used in the method are also described and claimed.